- Benzinga
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
Roche Holdings AG (OTC: RHHBY) released FY22 sales growth of 2% (+1% in CHF) to CHF 63.3 billion. Core operating profit increased by 3% (+1% in CHF), reflecting the good underlying business performance. The company warned that in 2023, a sharp decline in COVID-19 products would knock sales by around CHF 5 billion. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the company said. Related: FDA Approves Roche's Tocilizumab As First Monoclona
- Benzinga
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
Roche Holding Ltd (OTC: RHHBF) (OTC: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 Omicron sub-variant is prevalent in the U.S. and quickly spreads to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment stra
- Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study evaluates Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tecentriq combination showed a statistically significant improvement in RFS in t
